Compare Novartis AG (NVS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vertex Pharmaceuticals Incorporated — how do they compare? Novartis AG trades at $152.4 (market cap $295.37B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Novartis AG is far larger — about 2.2× Vertex Pharmaceuticals Incorporated's market cap, and Novartis AG pays a 3.07% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NVS | VRTX | |
|---|---|---|
Market Cap | $295.37B | $134.25B |
Sector | Health | Health |
52-Week High | $168.62 | $529.65 |
52-Week Low | $119.31 | $376.62 |
Enterprise Value | $336.69B | $128.37B |
Dividend Yield | 3.07% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
